Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients
暂无分享,去创建一个
C. Borg | D. Vernerey | Stefano Kim | F. Fein | E. Klajer | F. Calcagno | M. Jary | J. Henriques | S. Fratté | H. Almotlak | E. Orillard | A. Vienot